Celldex Therapeutics, Inc. — Operating Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/916d8a50-eca5-47b4-b248-edb83c16c5e4/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-287.4M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-019652 |
| FY 2024 | $-195.1M | 2024-01-01 – 2024-12-31 | evidence 0001410578-25-000216 |
| FY 2023 | $-154.5M | 2023-01-01 – 2023-12-31 | evidence 0001410578-24-000076 |
| FY 2022 | $-115.2M | 2022-01-01 – 2022-12-31 | evidence 0001104659-23-026701 |
| FY 2021 | $-71.2M | 2021-01-01 – 2021-12-31 | evidence 0001104659-22-028070 |
| FY 2020 | $-63.4M | 2020-01-01 – 2020-12-31 | evidence 0001104659-21-043161 |
| FY 2019 | $-55.0M | 2019-01-01 – 2019-12-31 | evidence 0001047469-20-001809 |
| FY 2018 | $-156.4M | 2018-01-01 – 2018-12-31 | evidence 0001047469-19-000992 |
| FY 2017 | $-121.5M | 2017-01-01 – 2017-12-31 | evidence 0001047469-18-001363 |
| FY 2016 | $-132.9M | 2016-01-01 – 2016-12-31 | evidence 0001047469-17-001564 |
| FY 2015 | $-129.5M | 2015-01-01 – 2015-12-31 | evidence 0001047469-16-010308 |
| FY 2014 | $-122.4M | 2014-01-01 – 2014-12-31 | evidence 0001047469-15-001081 |
| FY 2013 | $-81.4M | 2013-01-01 – 2013-12-31 | evidence 0001047469-14-001653 |
| FY 2012 | $-58.1M | 2012-01-01 – 2012-12-31 | evidence 0001047469-13-002403 |
| FY 2011 | $-43.4M | 2011-01-01 – 2011-12-31 | evidence 0001047469-12-002276 |
| FY 2010 | $-6.5M | 2010-01-01 – 2010-12-31 | evidence 0001047469-12-002276 |
| FY 2009 | $-36.9M | 2009-01-01 – 2009-12-31 | evidence 0001047469-12-002276 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Celldex Therapeutics, Inc. — all facts · Revenue · Net Income